A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB , a company discovering and developing ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January 23, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company dis ...

The investigational drug mesdopetam (IRL790), a dopamine D3 receptor antagonist, is being developed as a treatment for Parkinson's disease levodopa-induced dyskinesias (PD-LIDs). The objective is ...

University of Arizona researchers have advanced understanding of a common complication in Parkinson’s disease treatment: involuntary movements known as levodopa-induced dyskinesia. Published in Brain, ...

Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa. University of Arizona researchers have revealed new ...

In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given ...

University of Arizona researchers have revealed new insights into one of the most common complications faced by Parkinson's disease patients: uncontrollable movements that develop after years of ...